The effectiveness of transferring patients with open-angle glaucoma to therapy with a preservative-free fixed combination of a carbonic anhydrase inhibitor and a prostaglandin analogue

Purpose: to analyze the effectiveness of transferring open-angle glaucoma patients to therapy with a preservative-free fixed combination of a carbonic anhydrase inhibitor and a prostaglandin analogue. Material and methods. The study involved 58 people (24 men and 34 women), averagely aged 61.2 ± 7.1, diagnosed with stages II–III POAG and degree of compensation a-b (according to the Nesterov-Bunin classification). The patients were divided into three groups. Initally, Group 1 (22 people, 30 eyes) had received monotherapy with a beta-blocker (timolol), Group 2 (20 people, 27 eyes) had received monotherapy with the original prostaglandin analogue drug (latanoprost), and Group 3 (16 person, 19 eyes) had had therapy with the original drug, namely a fixed combination of a beta-blocker (timolol) and a prostaglandin analogue (latanoprost)). All patients were prescribed antihypertensive therapy with a fixed combination of a carbonic anhydrase inhibitor (dorzolamide) and a prostaglandin analogue (latanoprost) — the drug Dorzoprost, which was administered according to the standard regimen. We assessed the dynamics of intraocular pressure (IOP), perimetric indices, morphometric indicators of the optic nerve, tolerability of the drug regarding the effect on the ocular surface and safety regarding potential systemic side effects. Results. After 1 month of therapy, IOP significant decreased by 7.5 mm Hg (32 % of the initial value) in Group 1, by 3.7 mm Hg (19 %) in Group 2, and by 1 mm Hg (5 %) in Group 3. At month 3 and month 6, the hypotensive effect stabilized with respect to the previous control measurements (taken at 1 month) in all three groups. The morphometry of the optic nerve and the dynamics of perimetric indices showed no progression of glaucomatous optic neural opticopathy and no local or systemic undesirable effects of the therapy that could affect the compliance of the treatment. Conclusion. The Dorzoprost drug has demonstrated a high hypotensive efficiency when transferring patients from various basic therapy regimens and can be considered the drug of choice for patients with symptoms of keratoconjunctival xerosis and concomitant organ pathology requiring the use of systemic β-blockers.

1. Razhko Yu.I., Glushnev I.A., Rebenok N.A., Kuroyedov A.V., Brezhnev A.Yu. Novel approaches to glaucoma treatment (review of patents). Natsional’nyy zhurnal Glaukoma. 2021; 20 (2): 72–80 (In Russ.). https://doi.org/10.53432/2078-4104-2021-20-2-72-80

2. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002; 120 (10): 1268–79.

3. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004 Apr; 15 (2): 119–26. doi: 10.1097/00055735-200404000-00011

4. Dereglazova Yu.S. Analysis of the pharmaceutical market of drugs for glaucoma treatment. Volgograd Scientific and Medical Journal. 2021; 1: 38–40 (In Russ.). https://cyberleninka.ru/article/n/analiz-farmatsevticheskogo-rynka-lekarstvennyh-preparatov-dlya-lecheniya-glaukomy

5. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs. 2000 Mar; 59 (3): 411–34. doi: 10.2165/00003495-200059030-00003

6. Lovpache D.N., Arakelyan M.A., Ramazanova K.A. Hypotensive efficacy, tolerability and safety of timolol 0.5 %, dorzopt 2 %, combination of timolol 0.5 % and dorzopt 2 % in the treatment of patients with primary open-angle glaucoma. Russian ophthalmologic journal. 2011; 4 (1): 40–3 (In Russ.).

7. Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005 Oct; 89 (10): 1293–7. doi: 10.1136/bjo.2005.067637

8. Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Survey of Ophthalmology. 2009; 54 (1): 33–46. https://doi.org/10.1016/j.survophthal.2008.06.00210

9. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005 % latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102 (12): 1743–52. doi: https://doi.org/10.1016/S0161-6420(95)30798-1

10. Agafonova T.Yu., Sobyanin N.A., Gavrilova T.V. Progression of primary openangle glaucoma in type 2 diabetes: comorbidity issue. RMJ. Clinicheskaya oftalmologiya. 2017; 1: 22–5 (In Russ.). https://doi.org/10.21689/2311-7729-2017-17-1-22-25

11. Astakhov Yu.S., Akopov E.L., Nefedova D.M. Vascular risk factors in primary open-angle glaucoma. RMJ. Clinicheskaya oftalmologiya. 2008; 2: 68–70 (In Russ.).

12. Kiseleva O.A., Kosakyan S.M., Yakubova L.V., Vasilenkova L.V. Interaction of antiglaucomatous drugs in patients with chronic concomitant diseases. RMJ. Clinicheskaya oftalmologiya. 2016; 1: 16–9 (In Russ.).

13. Sychjov D.A., Moshetova L.K. Clinical and pharmacological aspects of combined pathology: cardiovascular diseases and glaucoma. Natsional’nyy zhurnal Glaukoma. 2014; 2: 99–104 (In Russ.).

14. Kogan M.P., Novikova V.V., Sorokin E.L., Egorov V.V. The frequency and structure of diabetes mellitus among patients of the Khabarovsk branch of the Federal State Institution MNTK “Eye Microsurgery”, the specifics of their selection and preparation for ophthalmosurgery. Zdravookhraneniye Dal’nego Vostoka. 2010; 4: 39–43 (In Russ.).

15. Kogan M.P., Novikova V.V., Utkin S.I., Egorov V.V., Sorokin E.L. Assessment of severity of somatic condition of patients with type 2 diabetes mellitus before performing ophthalmic surgery and features of their preoperative preparation. Vestnik Orenburgskogo gosudarstvennogo universiteta. 2013; 4: 139–44 (In Russ.).

16. Filimonova Е.E., Sorokin Е.L., Esina M.A., Pavlyushchenko L.V. The use of β-blockers in patients with glaucoma, the possibility of predicting and minimizing the risk of side effects (literature review). Modern Technologies in Ophthalmology. 2020; 2: 225–32 (In Russ.). https://doi.org/10.25276/2312-4911-2020-1-225-232

17. Korneeva A.V., Kuroyedov A.V., Zavadsky P.Ch., et al. Adherence to antihypertensive therapy for glaucoma: patients’ opinions about the key factors of low compliance. Results of a multicenter interactive scientific and analytical study. Natsional’nyy zhurnal Glaukoma. 2020; 19 (3): 12–21 (In Russ.). https://doi.org/10.25700/NJG.2020.03.02

18. Watson PA. 7 year prospective comparative study of three topical β-blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 2001Aug; 85 (8): 962–8. doi: 10.1136/bjo.85.8.962